Last reviewed · How we verify
NCT05477836: MiWEndo1
Feasibility and Safety of MiWEndo-assisted Colonoscopy
NA trial testing MiWEndo-assisted colonoscopy in Colorectal Cancer in 15 participants. Completed in 25 November 2022.
25 November 2022
Quick facts
| Lead sponsor | MiWEndo Solutions S.L. |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | device feasibility |
| Enrollment | 15 |
| Start date | 18 October 2022 |
| Primary completion | 25 November 2022 |
| Estimated completion | 25 November 2022 |
| Sites | 1 location across Spain |
Drugs / interventions tested
- MiWEndo-assisted colonoscopy
Conditions studied
- Colorectal Cancer — all drugs for Colorectal Cancer →
- Colorectal Polyp — all drugs for Colorectal Polyp →
- Colorectal Adenoma — all drugs for Colorectal Adenoma →
- Colorectal Neoplasms — all drugs for Colorectal Neoplasms →
Sponsor
MiWEndo Solutions S.L.
Who can join
50 and older, any sex, with Colorectal Cancer or Colorectal Polyp. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The study involves the planned use of a new microwave-based device during colonoscopy procedures in a small group of patients to assess the preliminary safety of its use and lack of normal clinical practice modification. The device is a final design version, which has been previously tested in several preclinical studies, including: phantom studies, an ex vivo study with human tissues, and an in vivo study with animal model (pig).
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
New Concept of Colonoscopy Assisted by a Microwave-Based Accessory Device: First Clinical Experience.
Ortiz O, Sendino O, Rivadulla S, Garrido A, et al · · 2025 · cited 1× · PMID 40227570 · DOI 10.3390/cancers17071073
Verify or expand the search:
- PubMed search for NCT05477836
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Colorectal Cancer
Currently open trials in the same condition.
- NCT07152821 — Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcino · Phase 3 · recruiting
- NCT07353645 — KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer · Phase 1, PHASE2 · recruiting
- NCT07432633 — [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications · Phase 1, PHASE2 · recruiting
- NCT07523919 — Functional and Respiratory Determinants of Long-Term Colorectal Cancer Outcomes · recruiting
- NCT07529301 — Functional and Respiratory Predictors of Early Postoperative Outcomes · recruiting
Other MiWEndo Solutions S.L. trials
Trials by the same sponsor.
- NCT05988645 — Performance and Safety of MiWEndo-assisted Colonoscopy (MiWEndo II) · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05477836 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by MiWEndo Solutions S.L.
- Last refreshed: 30 November 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05477836.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing